✅ The verified answer to this question is available below. Our community-reviewed solutions help you understand the material better.
Following widespread vaccination and natural infection, much of the human population has partial immunity to SARS‑CoV‑2. A new variant arises that is less effectively neutralised by existing antibodies, while retaining strong ACE2 binding and efficient transmission. The variant shows no increased virulence or replication cost.
If introduced into such a population, what outcome is most likely over time?